COLL
Price
$25.60
Change
-$0.03 (-0.12%)
Updated
Dec 1, 6:59 PM EST
82 days until earnings call
DVAX
Price
$13.79
Change
+$0.09 (+0.66%)
Updated
Dec 1, 6:59 PM EST
87 days until earnings call
Ad is loading...

Compare trend and price COLL vs DVAX

Header iconCOLL vs DVAX Comparison
Open Charts COLL vs DVAXBanner chart's image
Collegium Pharmaceutical
Price$25.60
Change-$0.03 (-0.12%)
Volume$134.11K
CapitalizationN/A
Dynavax Technologies
Price$13.79
Change+$0.09 (+0.66%)
Volume$1.14M
CapitalizationN/A
View a ticker or compare two or three
COLL vs DVAX Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
COLL vs. DVAX commentary
Dec 03, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COLL is a Hold and DVAX is a Buy.

COMPARISON
Comparison
Dec 03, 2023
Stock price -- (COLL: $25.62 vs. DVAX: $13.78)
Brand notoriety: COLL and DVAX are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: COLL: 74% vs. DVAX: 100%
Market capitalization -- COLL: $843.32M vs. DVAX: $1.76B
COLL [@Pharmaceuticals: Other] is valued at $843.32M. DVAX’s [@Pharmaceuticals: Other] market capitalization is $1.76B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $82.08B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COLL’s FA Score shows that 2 FA rating(s) are green whileDVAX’s FA Score has 1 green FA rating(s).

  • COLL’s FA Score: 2 green, 3 red.
  • DVAX’s FA Score: 1 green, 4 red.
According to our system of comparison, COLL is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COLL’s TA Score shows that 6 TA indicator(s) are bullish while DVAX’s TA Score has 6 bullish TA indicator(s).

  • COLL’s TA Score: 6 bullish, 4 bearish.
  • DVAX’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, DVAX is a better buy in the short-term than COLL.

Price Growth

COLL (@Pharmaceuticals: Other) experienced а -1.61% price change this week, while DVAX (@Pharmaceuticals: Other) price change was +1.62% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.45%. For the same industry, the average monthly price growth was +39.13%, and the average quarterly price growth was -6.49%.

Reported Earning Dates

COLL is expected to report earnings on Feb 22, 2024.

DVAX is expected to report earnings on Feb 27, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (+3.45% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
A.I.dvisor published
a Summary for COLL with price predictions.
OPEN
A.I.dvisor published
a Summary for DVAX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
DVAX($1.76B) has a higher market cap than COLL($843M). COLL has higher P/E ratio than DVAX: COLL (106.38) vs DVAX (32.36). DVAX YTD gains are higher at: 29.511 vs. COLL (10.431). COLL has higher annual earnings (EBITDA): 263M vs. DVAX (76.1M). DVAX has more cash in the bank: 720M vs. COLL (305M). DVAX has less debt than COLL: DVAX (257M) vs COLL (718M). COLL has higher revenues than DVAX: COLL (547M) vs DVAX (361M).
COLLDVAXCOLL / DVAX
Capitalization843M1.76B48%
EBITDA263M76.1M346%
Gain YTD10.43129.51135%
P/E Ratio106.3832.36329%
Revenue547M361M152%
Total Cash305M720M42%
Total Debt718M257M279%
FUNDAMENTALS RATINGS
COLL vs DVAX: Fundamental Ratings
COLL
DVAX
OUTLOOK RATING
1..100
179
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
3081
SMR RATING
1..100
8468
PRICE GROWTH RATING
1..100
4152
P/E GROWTH RATING
1..100
322
SEASONALITY SCORE
1..100
65n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DVAX's Valuation (68) in the Biotechnology industry is in the same range as COLL (83) in the Pharmaceuticals Other industry. This means that DVAX’s stock grew similarly to COLL’s over the last 12 months.

COLL's Profit vs Risk Rating (30) in the Pharmaceuticals Other industry is somewhat better than the same rating for DVAX (81) in the Biotechnology industry. This means that COLL’s stock grew somewhat faster than DVAX’s over the last 12 months.

DVAX's SMR Rating (68) in the Biotechnology industry is in the same range as COLL (84) in the Pharmaceuticals Other industry. This means that DVAX’s stock grew similarly to COLL’s over the last 12 months.

COLL's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as DVAX (52) in the Biotechnology industry. This means that COLL’s stock grew similarly to DVAX’s over the last 12 months.

DVAX's P/E Growth Rating (2) in the Biotechnology industry is in the same range as COLL (32) in the Pharmaceuticals Other industry. This means that DVAX’s stock grew similarly to COLL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COLLDVAX
RSI
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 5 days ago
70%
Bearish Trend 11 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
71%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HFDTX17.780.27
+1.54%
Hartford Schroders US MidCap Opps R5
KMVAX26.690.40
+1.52%
Kirr Marbach Partners Value
PFPFX49.620.63
+1.29%
Poplar Forest Partners A
MEIGX47.650.40
+0.85%
MFS Value R1
JDIVX15.110.12
+0.80%
JHancock Disciplined Value Intl NAV